Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681661 | 0.89 | — | — | |
| SCHEMBL701151 | 0.89 | — | — | |
| SCHEMBL5606967 | 0.89 | ALDH1A1 (0.40) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL5606971 | 0.89 | ALDH1A1 (0.40) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL4325997 | 0.83 | — | — | |
| SCHEMBL6474031 | 0.81 | ALDH1A1 (0.37) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL1052747 | 0.81 | ALDH1A1 (0.39) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL134842 | 0.81 | ALDH1A1 (0.37) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL1052754 | 0.81 | ALDH1A1 (0.39) | ALDH1A1GABRA1TSHRGABRG2RXRA | |
| SCHEMBL18543812 | 0.80 | GRIK1 (0.39) | ALDH1A1GABRA1TSHRGABRG2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463146-B2 | Addition-fragmentation oligomers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-10-11 | — | — | US | disclosed |
| US-9403966-B2 | Addition-fragmentation agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150328086-A1 | ADDITION-FRAGMENTATION OLIGOMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150203658-A1 | ADDITION-FRAGMENTATION AGENTS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-07-23 | — | — | US | disclosed |
| US-8980969-B2 | Addition-fragmentation agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20090264551-A1 | Photocurable fixture for orthopedic surgery background of the invention | ALCARE CO., LTD. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328086-A1 | ADDITION-FRAGMENTATION OLIGOMERS | FGB, ZYX, APBA1 | ALDH1A1 1881/4885GABRA1 1752/4885TSHR 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.